Relmada Therapeutics Inc (RLMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2019 | 03-2019 | 12-2018 | 09-2018 | 06-2018 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 9,217 | 2,054 | 2,427 | 888 | 2,239 |
| Receivables | 247 | 69 | 67 | 66 | 72 |
| TOTAL | $9,984 | $2,330 | $3,032 | $1,270 | $2,738 |
| Non-Current Assets | |||||
| PPE Net | 7 | 8 | 9 | 11 | 12 |
| Other Non-Current Assets | 228 | 265 | 258 | 275 | 298 |
| TOTAL | $235 | $273 | $267 | $286 | $310 |
| Total Assets | $10,220 | $2,604 | $3,299 | $1,556 | $3,048 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 924 | 1,080 | 359 | 1,019 | 765 |
| Accrued Expenses | 1,318 | 1,021 | 1,391 | 966 | 660 |
| Other current liabilities | N/A | N/A | N/A | 4,918 | 4,195 |
| TOTAL | $2,606 | $2,130 | $1,864 | $7,103 | $5,905 |
| Non-Current Liabilities | |||||
| Long Term Debt | N/A | N/A | N/A | 3,193 | 2,657 |
| TOTAL | $N/A | $N/A | $N/A | $3,193 | $2,657 |
| Total Liabilities | $2,606 | $2,130 | $1,864 | $10,296 | $8,561 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | N/A | 8,314 | 7,567 | 7,106 | N/A |
| Common Shares | 10 | 31 | 30 | 13 | 13 |
| Retained earnings | -111,662 | -107,540 | -104,854 | -97,724 | -94,344 |
| TOTAL | $7,613 | $474 | $1,435 | $-8,740 | $-5,513 |
| Total Liabilities And Equity | $10,220 | $2,604 | $3,299 | $1,556 | $3,048 |